IONIS PHARMACEUTICALS INC 4

Non-employee director Michael R. Hayden received stock options for 5,369 shares at $79.19 and 2,301 RSUs of Ionis Pharmaceuticals on July 1, 2026 as part of his annual equity compensation.

On July 1, 2026, Ionis Pharmaceuticals non-employee director Michael R. Hayden received routine equity compensation consisting of a non-qualified stock option to purchase 5,369 shares of common stock at an exercise price of $79.19 per share and a restricted stock unit award covering 2,301 shares, both granted under the company’s non-employee director stock option plan. These awards were structured so that his total 2026 annual director equity compensation does not exceed $400,000 in grant date fair value under ASC 718, and both the options and RSUs vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting, with the RSUs further subject to a deferral election for delivery upon separation from service or a change in control. Following these grants, Hayden holds 12,198 shares or share equivalents of Ionis common stock in direct ownership.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000228

Alert Tier

5